Sagimet Biosciences Inc. (Series A) (SGMT) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Sagimet Biosciences Inc. (Series A) (NASDAQ: SGMT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $9.69 (-2.32% 1D, market cap $699.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SGMT ranks #439 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SGMT carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, WVE (Wave Life Sciences Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $708.1M) and APMD (Apnimed Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $682.7M). Among the 5-stock peer group, SGMT leads on earnings multiple (N/A) while DSGN leads on capital efficiency (-32.1% ROIC).
Per SGMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001400118), Sagimet Biosciences Inc. (Series A) generated $159.3M in revenue (+4.5% YoY), -$51.0M in net income, and -$45.6M in free cash flow against $116.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While SGMT currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.93) and Max Pain ($10.17) forces dealer call-delta covering toward $12.02.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Sagimet Biosciences Inc. (Series A) (SGMT) dropped -2.32% to $9.69, trading at 75% of its 52-week range ($4.5 – $11.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regula
The consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announced that its strategic partner, Sagimet Biosciences Inc. ("Sagimet"), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner AscletisPivotal trial des
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner AscletisPivotal
SGMT pivots denifanstat to acne with Phase 3 data and a funded U.S. registrational trial.
Sagimet Biosciences Inc. (SGMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +4.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SGMT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SGMT. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Sagimet Biosciences Inc. (Series A) (SGMT) ranks #439 by composite RQD confidence (41/100, grade D-) and #395 by equity capitalization ($699.7M). Within this direct 5-issuer industry benchmark cohort, SGMT leads on earnings valuation at N/A trailing P/E, while DSGN leads on capital efficiency and profitability with -32.1% ROIC and — gross margin. APMD currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with SGMT at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SGMT
ACTIVE
Sagimet Biosciences Inc. (Series A) | D- | 41/100 | — | — | -35.0% | -2.32% | $699.7M | Benchmark Subject |
| WVE Wave Life Sciences Inc. | E | 22/100 | — | — | -35.0% | -1.95% | $708.1M | /wve-vs-sgmt → |
| APMD Apnimed Inc. | D- | 43/100 | — | — | — | -6.10% | $682.7M | /apmd-vs-sgmt → |
| DSGN Design Therapeutics Inc. | E | 33/100 | — | — | -32.1% | -4.96% | $668.4M | /dsgn-vs-sgmt → |
| AVBP ArriVent BioPharma Inc. | E | 29/100 | — | — | -35.0% | -10.22% | $733.2M | /avbp-vs-sgmt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sagimet Biosciences Inc. (Series A) (SGMT) reported GAAP revenue of $159.3M (+4.5% vs. FY2024 revenue of $152.5M , and +7864.5% cumulative change since FY2023) , GAAP net income of -$51.0M, operating cash flow of -$45.6M, and free cash flow of -$45.6M (-7.6% YoY). On the balance sheet, SGMT closed FY2025 with $116.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $159.3M | -$51.0M | -$45.6M | -$45.6M | $116.5M | — |
| FY2024 (FY) | 2024-12-31 | $152.5M | -$45.6M | -$42.4M | -$42.4M | $160.3M | — |
| FY2023 (FY) | 2023-12-31 | $2.0M | -$27.9M | -$23.8M | -$23.8M | — | — |
As of 2026-11-03, Sagimet Biosciences Inc. (Series A) (NASDAQ: SGMT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $9.69 (-2.32% 1D, market cap $699.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SGMT ranks #439 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SGMT carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, WVE (Wave Life Sciences Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $708.1M) and APMD (Apnimed Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $682.7M). Among the 5-stock peer group, SGMT leads on earnings multiple (N/A) while DSGN leads on capital efficiency (-32.1% ROIC).
Per SGMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001400118), Sagimet Biosciences Inc. (Series A) generated $159.3M in revenue (+4.5% YoY), -$51.0M in net income, and -$45.6M in free cash flow against $116.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
SGMT last traded at $9.69 (-2.32% on volume of 736,101 shares), positioning the stock -2.42% below its 50-day simple moving average ($9.93) and +28.51% above its 200-day simple moving average ($7.54). Across its 52-week range of $4.50 to $11.45, SGMT sits at the 74.7% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.48 to $10.90).
Sagimet Biosciences Inc. (Series A) (SGMT) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $9.69 (-2.32% 1D, market capitalization $699.7M).
And profile, Sagimet Biosciences Inc. (Series A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — for FY 2025 and FY 2024, with $2.0M reported for FY 2023..7B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Sagimet Biosciences Inc. (Series A) (SGMT) reported $159.3M in annual revenue (up from $152.5M in FY2024, +4.5% YoY) and -$51.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.0M revenue, -$27.9M net income) through FY2025, SGMT scaled operating cash flow to -$45.6M and free cash flow to -$45.6M, backed by $116.5M in total assets against $0 in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), SGMT carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Sagimet Biosciences Inc. (Series A) (SGMT) • Click "Debate This Headline" to argue it in the Roar Pit below
FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regula
The consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announced that its strategic partner, Sagimet Biosciences Inc. ("Sagimet"), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner AscletisPivotal trial des
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner AscletisPivotal
SGMT pivots denifanstat to acne with Phase 3 data and a funded U.S. registrational trial.
Sagimet Biosciences Inc. (SGMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn
Picked up a starter position in SGMT in my $100K Virtual Cash book at $9.92. Institutional accumulation and options positioning earn the highest pillar score (15/20), signaling some institutional interest despite weak fundamentals.. Trading inside a $4.50–$11.45 52-week range with -6.21% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
@QuantViper Agree on the RQD 41/100 quality, though with 1.0 beta I'm scaling in with half-size at $9.92 and keeping dry powder in case we test $9.23.
Careful chasing SGMT at $9.92. With ROIC of -35%, FCF yield of -6.21%, and a Piotroski F-Score of 2/9, the company is burning cash with no earnings floor under a $735.7M market capitalization.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $8.23 on multiple compression.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).